Regulatory support for Choroideremia treatment from Nightstar

Nightstar, a spin-out from the University of Oxford in 2014 has received both U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Orphan Drug Designation for its lead programme, a gene therapy to treat Choroideremia, an X-linked recessive disorder that leads to progressive blindness.

Read more

TheySay – the Zeitgeist in the Machine

TheySay, spun out by Oxford University Innovation in 2011, is an advanced text and sentiment analytics company. The company has developed a platform which analyses huge amounts of unstructured text in real time, and will be monitoring the 2015 General Election.  

Read more

Nightstar Ltd increases funding to £17 million

Nightstar, which was spun out in 2014 raising £12 million from Syncona, the venture arm of the Wellcome Trust, has received additional finance from its key investors to advance the company’s clinical choroideremia programme.

Read more

Sparks Background Image

Ready to get in touch?

Contact Us
Sparks Background Image
© Oxford University Innovation